SALEM, Mass., April 27 /PRNewswire/ -- LaVoie Group, a life science-focused strategic communications agency, announced today that it has been selected as investor relations agency of record for Pegasus Biologics, Inc.
Donna L. LaVoie, President & CEO of LaVoie Group, commented, "Pegasus has the opportunity to capture the significant market share in the bio-surgery area. The Company is changing the standard of care in three initial markets: limb preservation, orthopedics, and shortly in ventral hernia repair. The addition of Pegasus underscores the increasingly diverse nature of our life sciences roster."
Michael Will, Chief Executive Officer of Pegasus Biologics, commented, "LaVoie Group has the necessary experience, skills and relationships to help capture our corporate story and articulate it to our target investor audiences. Their perspective and creative approach is already proving invaluable as we work to communicate our value proposition."
About Pegasus Biologics
Pegasus Biologics, Inc. (Irvine, CA) is a commercialization-stage company with products expected to change the standard of care in the bio-surgery solution market. Additional information on the Company can be found at http://www.pegasusbio.com.
About LaVoie Group, Inc.
LaVoie Group provides senior-level strategic counsel and tactical implementation of venture, investor and public relations programs designed to properly position, create visibility and drive value for each client. We help our life sciences companies attract capital, reach corporate partners, generate revenue and build their companies through integrated communications programs. In addition to Pegasus, our clients range from privately held development stage companies to industry leaders in life sciences such as
|SOURCE LaVoie Group|
Copyright©2009 PR Newswire.
All rights reserved